Suppr超能文献

甘草次酸及其衍生物可作为非住院 COVID-19 患者症状缓解的潜在替代药物。

Glycyrrhetinic acid and its derivatives as potential alternative medicine to relieve symptoms in nonhospitalized COVID-19 patients.

机构信息

Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Ministry of Education, Wuhan University School of Pharmaceutical Sciences, Wuhan University, Wuhan, China.

Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts.

出版信息

J Med Virol. 2020 Oct;92(10):2200-2204. doi: 10.1002/jmv.26064. Epub 2020 Jun 5.

Abstract

SARS-CoV-2 is highly infectious, and infection by this virus results in COVID-19, manifesting predominantly symptoms in the lower respiratory system. Detection of viral genomic materials by RT-PCR is the gold standard for diagnosis. Suspected COVID-19 patients who had a documented history of exposure and exhibited symptoms, but did not have positive PCR test results, were generally self-quarantined with prescriptions aiming to help attenuate their symptoms. These prescriptions are however neither specific nor highly effective for COVID-19 treatment. Given the rapidly growing pandemic and the overwhelmed medical system, the number of self-quarantined patients is increasing. There is an urgent need of alternative medicine to help patients relieve symptoms during self-quarantine, and to potentially help increase their chances of survival and recovery from the infection. We report here a case of severe COVID-19 that never had a positive PCR test result during disease progression but was confirmed with antibody test post recovery. This patient was self-quarantined and received diammonium glycyrrhizinate (DG), a steroid-like molecule, in combination with vitamin C as alternative medicine. This patient went through severe COVID-19 but eventually recovered upon the implementation of this treatment regimen, suggesting potential therapeutic effects of DG as alternative medicine to help relieve COVID-19 symptoms.

摘要

SARS-CoV-2 具有高度传染性,感染该病毒会导致 COVID-19,主要表现为下呼吸道症状。通过 RT-PCR 检测病毒基因组物质是诊断的金标准。有明确接触史且出现症状但 PCR 检测结果为阴性的疑似 COVID-19 患者通常会自行隔离,并开具旨在缓解症状的处方。然而,这些处方既不是 COVID-19 治疗的特效药,也不是特效药。鉴于疫情迅速蔓延和医疗系统不堪重负,自行隔离的患者人数不断增加。因此,急需替代药物来帮助患者在隔离期间缓解症状,并有可能帮助提高他们的生存和康复几率。我们在此报告一例严重 COVID-19 病例,该患者在疾病进展过程中从未出现过阳性 PCR 检测结果,但在康复后通过抗体检测得到确认。该患者接受了甘草酸二铵(DG)和维生素 C 的联合治疗,这是一种类固醇样分子,作为替代药物进行自我隔离。这名患者经历了严重的 COVID-19,但在实施该治疗方案后最终康复,这表明 DG 作为替代药物可能具有缓解 COVID-19 症状的治疗效果。

相似文献

4
SARS-CoV-2 shedding and seroconversion among passengers quarantined after disembarking a cruise ship: a case series.
Lancet Infect Dis. 2020 Sep;20(9):1051-1060. doi: 10.1016/S1473-3099(20)30364-9. Epub 2020 Jun 12.
9
High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR.
Eur J Cancer. 2020 Aug;135:251-259. doi: 10.1016/j.ejca.2020.05.028. Epub 2020 Jun 7.

引用本文的文献

3
A review of typical biological activities of glycyrrhetinic acid and its derivatives.
RSC Adv. 2024 Feb 22;14(10):6557-6597. doi: 10.1039/d3ra08025k. eCollection 2024 Feb 21.
4
Nebulized glycyrrhizin/enoxolone drug modulates IL-17A in COVID-19 patients: a randomized clinical trial.
Front Immunol. 2024 Jan 12;14:1282280. doi: 10.3389/fimmu.2023.1282280. eCollection 2023.
5
Integrated Immunopeptidomic and Proteomic Analysis of COVID-19 lung biopsies.
Front Immunol. 2023 Oct 20;14:1269335. doi: 10.3389/fimmu.2023.1269335. eCollection 2023.
7
Glycyrrhizin as a promising kryptonite against SARS-CoV-2: Clinical, experimental, and theoretical evidences.
J Mol Struct. 2023 Mar 5;1275:134642. doi: 10.1016/j.molstruc.2022.134642. Epub 2022 Nov 25.
8
New Aspects of the Antioxidant Activity of Glycyrrhizin Revealed by the CIDNP Technique.
Antioxidants (Basel). 2022 Aug 17;11(8):1591. doi: 10.3390/antiox11081591.
9
Synthesis, Antiviral, and Antibacterial Activity of the Glycyrrhizic Acid and Glycyrrhetinic Acid Derivatives.
Russ J Bioorg Chem. 2022;48(5):906-918. doi: 10.1134/S1068162022050132. Epub 2022 Jul 28.

本文引用的文献

1
COVID-19 diagnostic process in mainland China: The math beyond pneumonia.
J Allergy Clin Immunol. 2020 Jul;146(1):64-66. doi: 10.1016/j.jaci.2020.04.015. Epub 2020 Apr 25.
2
Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective.
Eur Respir J. 2020 May 7;55(5). doi: 10.1183/13993003.01009-2020. Print 2020 May.
3
COVID-19: immunopathology and its implications for therapy.
Nat Rev Immunol. 2020 May;20(5):269-270. doi: 10.1038/s41577-020-0308-3.
4
An investigation of transmission control measures during the first 50 days of the COVID-19 epidemic in China.
Science. 2020 May 8;368(6491):638-642. doi: 10.1126/science.abb6105. Epub 2020 Mar 31.
5
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
6
Redeploying plant defences.
Nat Plants. 2020 Mar;6(3):177. doi: 10.1038/s41477-020-0628-0.
7
Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China.
Sci China Life Sci. 2020 May;63(5):706-711. doi: 10.1007/s11427-020-1661-4. Epub 2020 Mar 4.
8
Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury.
Lancet. 2020 Feb 15;395(10223):473-475. doi: 10.1016/S0140-6736(20)30317-2. Epub 2020 Feb 7.
10
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.
Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验